Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Ophthalmology
•
Cornea and External Disease
When should mitomycin intravascular chemoembolization be considered as a treatment for corneal neovascularization?
Related Questions
In patients with sicca symptoms and positive SSA/SSB how often do you perform other diagnostic testing such as salivary gland ultrasound, biopsy, Shirmers, ocular staining, stimulated salivary flow, etc?
What factors influence your decision to pursue surgical management in cases of infectious keratitis caused by multidrug-resistant pathogens?
How do you approach IOL calculations and selection in patients with keratoconus based on disease severity?
How do you determine the role of adjunctive therapies for a patient with conjunctival squamous cell carcinoma (SCC) that has recurred after initial surgical excision?
How would you approach the management of a patient presenting with bilateral central corneal perforations following treatment with Ipilimumab/Nivolumab?
How do you approach IOL exchange in a patient who is unhappy after cataract surgery with a premium IOL?
What strategies do you use to optimize cataract surgery outcomes in patients with anterior basement membrane dystrophy (ABMD)?
What has been your experience with netarsudil in the management of corneal edema, particularly concerning its clinical effectiveness and insurance coverage?
Which IOL do you prefer for patients with a history of hyperopic LASIK to minimize the risk of inducing spherical aberration?
How would you approach the management of dry corneal melt in a patient requiring high dose systemic steroids and no apparent underlying systemic autoimmune disease?
